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the condition/controls (employees without condition) were: BPD 239/85,420; OMD 
5508/76,372; CC 920/143,287; FD 918/143,138; GERD 6172/133,466; gout
600/123,461; and insomnia 7951/134,094. All incremental SL cost differences
were signiﬁ cant (P  0.05). From highest to lowest, the incremental annual SL costs 
(condition-control) were: gout  $359(172.5% higher than controls), insomnia
 $208(162.1%), OMD  $175(142.4%), GERD  $169(141.1%), CC 
$127(133.8%), FD  $120(128.8%), BPD  $94(119.7%). From highest to lowest, 
the incremental annual absence days were: gout  2.8(178.3% of control), OMD 
2.3(186.9%), BPD  1.9(157.0%), insomnia  1.6(175.4%), GERD  1.3(141.5%),
FD  0.8(126.7%), and CC  0.7(130.5%). CONCLUSIONS: Employees with insom-
nia, FD, GERD, gout, CC, BPD, and OMD incur more absences and costs than
employees without these conditions, suggesting that management of these conditions 
should focus on both the workplace and health care settings. Because individual sala-
ries were used to calculate the costs for each condition, the differences in the ordering
of the incremental days and payments may be attributable to job-related differences
between the diseases. Gout had the highest incremental costs and days of any of the 
studied conditions.
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OBJECTIVES: To determine whether improving quality of care saves money we
examined costs and beneﬁ ts of increasing compliance with the 2006 Healthcare
Effectiveness Data and Information Set (HEDIS) measures. METHODS: We systemati-
cally reviewed English-language scientiﬁ c literature (1998–2008) for US or Western
European cost effectiveness analyses published as original articles that compared
HEDIS-compliance to non-compliance and reported cost and beneﬁ ts. We abstracted 
costs, effectiveness, and incremental cost effectiveness ratios (ICER). Using US Census 
data, we calculated the total annual cost and beneﬁ t associated with moving from
2006 HEDIS rates to 95% compliance. RESULTS: We screened 1641 articles, reviewed 
222, and accepted 18 (relating to 19 of 25 measures). Greater compliance with 6 
measures reduced costs. Increasing compliance with the remaining 13 measures
increased costs but improved health; ICERs varied from $180/quality-adjusted-life-
year (QALY) (initiation of alcohol/drug treatment) to $39,805/QALY (breast cancer
screening). The number of people required to reach 95% compliance varied from 0
for beta-blocker use after MI (2006 compliance 96.6%) to 39 million for ﬂ u shots 
(2006 compliance 44.5%%). The most costly measure was comprehensive diabetes 
care ($7 billion/year) and the least costly were increasing childhood immunizations 
and reducing inappropriate imaging studies for back pain (each saving almost $400 
million/year). 95% compliance on all measures would cost $13.2 billion annually, save
$1 billion (net $12.2 billion), and add 7 million QALYs for a mean overall cost effec-
tiveness of under $2000/QALY. CONCLUSIONS: Improving quality using a nation-
ally accepted list of quality measures would increase, not reduce, costs. A published
study estimated that recent medical advances have improved health at a cost of $30–
$85,000/QALY; in comparison, improving compliance with HEDIS measures may be
an attractive investment. If more HEDIS measures examined overuse (e.g. of treat-
ments with inadequate evidence of effectiveness), improving compliance with the entire
set might reduce costs.
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OBJECTIVES: Uncertain decisions made using a cost-effectiveness threshold applied 
to each decision problem separately fail to identify the true opportunity costs of displac-
ing other unrelated programmes. We show that the allocation problem can be charac-
terised to provide a more general and comprehensive approach to informing adoption 
and research decisions. METHODS: A stochastic mathematical programming approach
is used to solve the allocation problem. The formulation allows the characterisation of 
actual budgetary policies, including a strict budgetary rule where deﬁ cits are not pos-
sible and constraints must always be met. The opportunity costs (health forgone due 
to curtailing some programmes and treatments) of violating the budget constraint are 
incorporated directly. In addition, the value of acquiring new evidence to inform the
allocation problem in light of its current uncertainty is considered simultaneously and 
consistently. RESULTS: The allocation and research decision problem depends on a 
number of considerations: 1) size of overall budget; 2) budgetary policy in place; 3)
information that is revealed and its timing; 4) subsequent actions available to decision
makers; and 5) costs of effectively monitoring ex-ante plans. Standard decision rules 
in cost-effectiveness analysis are only optimal under very special circumstances, which 
require budget constraints to be soft in addition to assumptions of perfect divisibility,
constant returns and all costs and beneﬁ ts occurring within the budgetary period.
However, if the budget constraint is hard then technologies will need to be more cost-
effective (an incremental cost-effectiveness ratio substantially below the threshold)
before the decision maker should take the risk of an ex-ante decision to adopt them. 
CONCLUSIONS: Standard decision rules and measures of value are proxies for an 
uncertain and complex process. There are no simple ex-ante decision rules in most
common circumstances and the value of information cannot be established for one 
programme independently of the rest of the allocation problem.
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OBJECTIVES: Reimbursement for the same drug may differ with respect to channel
of distribution. The objective of this study was to assess differences in reimbursement 
per unit of product dispensed and to compare pharmaceutical expenditures between 
mail-order and community pharmacy. METHODS: Pharmacy claims from a retire-
ment system for the period 2000–2005 were used in the analysis. Differences in reim-
bursement per unit of product dispensed and expenditures were estimated using a 
basket of drug items (i.e. unique combinations of drug products, formulations, 
strength, and generic status) dispensed in both channels. Rebates were not included 
in the analysis. Differences were assessed using bootstrapped 90% percentile and 
hybrid conﬁ dence intervals. RESULTS: The comparison basket contained 1,964 items 
and 4,001,243 claims. In 2005, 52.07% of the items had higher reimbursement per 
unit in community pharmacy, 35.80% had higher reimbursement in mail-order phar-
macy and 13.31% had equal reimbursement. In 2005, estimated pharmaceutical 
expenditures of the comparison basket were $558.93 million using mail-order phar-
macy prices and $623.66 million using community pharmacy prices. This difference 
was attributed to higher reimbursement of ingredient cost, administrative fees and 
dispensing fees in community pharmacy. The difference in estimated pharmaceutical
expenditures of the comparison basket between community and mail-order pharmacy 
decreased from 12.8% in 2000 to 10.4% in 2005. Estimated pharmaceutical expen-
ditures in both channels increased from 2000–2005. The difference in total expendi-
tures, ingredient cost, dispensing, administration and other fees between channels 
decreased during the study period. CONCLUSIONS: Nearly one-half of all compara-
ble items had higher reimbursement per unit in community pharmacy than mail-order 
pharmacy. Overall expenditures were signiﬁ cantly lower in mail-order pharmacy.
Differences in pharmaceutical expenditures between community and mail-order phar-
macy were explained by differences in acquisition costs and fees. Decision makers 
should carefully evaluate pharmaceutical reimbursement including discounts, fees and
rebates when deciding the most efﬁ cient dispensing channel.
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OBJECTIVES: To evaluate and compare trends in design characteristics of brief-
summary formats of prescription drug print ads. METHODS: The source for these 
ads include a consumer magazine – National Geographic (NG) and three medical
journals – Annals of Internal Medicine (AIM), The Journal of the American Medical 
Association (JAMA) and The New England Journal of Medicine (NEJM). Each source
was visually reviewed by research assistants to record information from brief sum-
maries on ads from issues dated January 1, 2000 through December 31, 2004. The
design characteristics evaluated were text font size, font consistency, presence of 
bullets, highlights, tables, graphs, format type (e.g.: question/answer format), warning 
box, spacing between lines, and number of columns used to present the material. Font
size was measured using the Compugraphic scale. Data were coded and analyzed using
SAS 9.1. Descriptive statistics and comparisons using chi-square tests were per-
formed to evaluate differences by year and source at a priori signiﬁ cance level of 0.05.
RESULTS: A total of 7266 printed ads for 240 products manufactured by 90 phar-
maceutical companies were evaluated from NG (95), AIM (1372), JAMA (1787), and 
NEJM (4012) respectively. There were signiﬁ cant differences (p  0.05) in most design
characteristics by year (2000–2004), namely font consistency, presence of bullets,
highlights, tables, graphs, and warning box. These differences were also statistically
signiﬁ cant (p  0.05) across sources (magazine/journals). The question/answer format
and presence of a warning box was mostly seen in ads obtained from the magazine. 
The mean (SD) font size of the text on these ads was small (5.7 o 1.1) and consistent 
throughout these ads by year and source. CONCLUSIONS: Prescription drug print 
ads have changed over the years and are different based on the readership source.
Further improvement in standardizing the format and increasing the text font may 
help the intended readers of these ads.
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OBJECTIVES: Globalization necessitates better co-ordination among countries to
monitor disease outbreaks. The spread of SARS in 2003 highlights this need. Hence,
this study compared the notiﬁ able diseases surveillance websites of four countries. 
METHODS: Twenty-ﬁ ve countries were identiﬁ ed from literature that had published 
Human Development Index 0.9 and Quality-of-Life index 7. Four countries from 
this list were selected, namely, United States (US), Canada, Australia, and New 
Zealand. Fourteen European Union member countries were excluded, as they have a 
process to harmonize and consolidate their disease surveillance networks in place by 
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2013. Seven other countries were excluded as either there was incomplete information 
(n  4) or information was partially in their native language (n  3). Parameters evalu-
ated were: number of diseases monitored, case deﬁ nition, presentation of data, and
periodicity of data presentation. Websites were accessed from December 4 – December
7, 2008. RESULTS: Information on the number of diseases monitored varied across
countries, namely, 64 (U.S.), 66 (Canada), 66 (Australia), and 51 (New Zealand), 
respectively. There was lack of consistency in case deﬁ nitions, data presentation, and 
the type of data accessed on their websites. The US presented raw data in the form 
of ‘Morbidity and Mortality Weekly Report’ and elaborated annual reports, available
unto 2006. Canada reported raw data monthly and annual reports available until
2004. Australia reported raw data fortnightly and annual reports available into 2006.
No such detailed information was available on the surveillance website for New
Zealand. CONCLUSIONS: There exists discrepancy in the disease surveillance web-
sites for the countries, in reporting surveillance data and related information. Infec-
tious diseases can achieve epidemiological proportions, hence, there needs to be more
concerted efforts in harmonizing structure of the surveillance networks and data pre-
sentation. Harmonization efforts taken by the ‘European Centre for Disease Preven-
tion and Control’ once published, may be considered by other countries.
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OBJECTIVES: To determine factors associated with repeat attendance at emergency 
department (ED) of a secondary care hospital in Singapore. METHODS: An analysis
of data from the EDWeb of all patients who attended ED between January 1, 2005 
and December 31, 2007 was performed. Variables considered in the analysis were age,
gender, race, date of attendance, and diagnosis based on ICD-9CM code. Frequency 
of ED attendance was categorized into index attendance, repeat attendance and high 
impact attendance. Index attendance refers to the ﬁ rst visit by the patient to the ED.
Repeat attendance refers to more than one visit by the same patient. High impact
attendance refers to patients with 5 ED visits. RESULTS: There was a total of 
141,642, 142,820, 160,096 ED attendances in 2005, 2006, and 2007, respectively. 
Of these, 22–24% were by elderly patients (65 years), and 27%–28% were repeat 
attendance. Repeat attendance rate increased with age, with highest rates among those
aged 75 years (36%–38%) and signiﬁ cantly higher among young males, older
females, and those presenting with chronic obstructive pulmonary disease, respiratory 
infections, pneumonia, diabetes and heart failure. High impact attendance comprised
7–11% of total attendance and have increased by 12% among persons aged 75 over 
the period 2005–2007. Majority (60%) were males. CONCLUSIONS: Repeat atten-
dance constitute more than one fourth of total ED attendance and is marked among
the elderly. Singapore’s aging population with its complex health needs is likely to 
make up an increasing proportion of the workload of ED staff in the coming years.
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OBJECTIVES: To examine the incidence of Medicare Part D enrollees potentially 
affected by drug-drug interactions (DDI) and associated hospitalization, ER visits and 
death. METHODS: A retrospective cohort study of 2006 Medicare Part D enrollees 
from six states (Alabama, California, Florida, Mississippi, New York, and Ohio) was 
conducted. Enrollees with Part D claims for either the object or precipitant (precipitant 
alters the effects/pharmacokinetics of object) drug identiﬁ ed to result in a drug-drug 
interaction were included. Enrollees were identiﬁ ed as having a DDI if the object and 
precipitant drug were taken during overlapping dates, with the ﬁ rst day of overlap 
being the DDI event date. Medicare Part A records for 2006 were evaluated to examine 
hospitalizations and ER visits within 30 days of an object drug precipitation of the 
potential DDI. The Medicare beneﬁ ciary ﬁ le was used to examine death. RESULTS:
Data were available for 2,707,769 enrollees. Overall, 15.3% of enrollees were taking 
an object and precipitant drug, thus being at risk for a potential DDI. After controlling
for age, gender, ethnicity, and comorbidities, the odds ratio for hospitalization and for
ER visits when comparing enrollees with a DDI to enrollees taking an object drug 
without DDI potential were: 1.57 and 1.57 for warfarin DDI’s; 1.28 and 1.48 for
digoxin DDI’s; 1.37 and 1.04 for beta-blocker DDI’s; 1.27 and 1.09 for ACE/ARB 
inhibitor DDI’s; 2.20 and 1.90 for methotrexate DDI’s; 1.37 and 1.23 for clonidine
DDI’s. Signiﬁ cant outcomes were not found for pimozide, MAOI/SSRI, and thiopurine 
DDI’s. There was no increase in risk of mortality. CONCLUSIONS: Potential DDIs
are still a signiﬁ cant problem among the elderly. Intervention strategies to reduce 
the incidence of potential DDI’s should be a priority in CMS quality assurance 
activities.
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OBJECTIVES: The pharmacovigilance guidances have been implemented in many 
well developed countries, but in the developing countries it remains largely unclear. 
The purpose of this study was to review the current status of post-marketing drug 
safety surveillance in developing countries as deﬁ ned by low and lower-middle-income
economies and to compare it with some of the developed countries as deﬁ ned 
by high-income economies. METHODS: Using Pubmed, EMBASE, Cochrane, text-
books, and Internet search engines, an extensive literature review on post-marketing
drug safety surveillance systems were reviewed in terms of regulatory policy,
organizational structure, adverse drug reaction (ADR) reports, and safety monitoring 
system. The available data in the developing countries namely India, Zambia, 
Tanzania, China, Cuba, Ukraine, Malaysia, Chile and South Africa were then 
compared with that in the developed countries namely Netherlands, UK, and the
United States. RESULTS: Some developing countries like China and India are 
establishing pharmacovigilance centers and appear to be actively involved in post 
marketing surveillance. A handful of developing countries have a well planned strategy 
for pharmacovigilance. Many countries such as Kenya and Ethiopia do not have an 
ADR reporting system. Paucity of trained and experienced personnel, ﬁ nancial 
resources, and availability and irrational use of herbal medicines are some of the 
major obstacles in planning a well organized and structured ADR reporting system. 
The developing countries also lack well deﬁ ned guidelines on risk management. 
CONCLUSIONS: There is a deﬁ nite need for drug safety programs in the developing 
countries given the fact that these countries differ markedly in terms of type of disease 
prevalence, patient genotype and environment. A cooperative and exhaustive
effort by the regulatory authorities, physicians, as well as the pharmaceutical industry 
will be needed in order to create a functioning pharmacovigilance system in these 
countries.
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OBJECTIVES: We aimed to investigate associations between health-related quality of 
life (HRQoL) and health service utilization and to investigate whether HRQoL has
an independent inﬂ uence on health service utilization in addition to socio-demographic 
and morbidity variables. METHODS: A retrospective cross-sectional design was 
carried out among primary care patients in mainland China. Health services utilization 
was measured by the number of monthly outpatient consultation and the annual 
hospitalization rate. HRQoL was measured by the SF-36. The clustered regression 
model was adopted to calculate the independent inﬂ uence of HRQoL on health service 
utilization in addition to socio-demographic and morbidity variables. A total of 733
valid subjects were eventually recruited in this study. RESULTS: Three of the SF-36
subscales were reversely associated with the outpatient consultation, whereas two of 
the SF-36 subscales were reversely associated with inpatient consultation. In addition
to socio-demographic and morbidity variables, one subscale of the SF-36 (mental 
health) was reversely associated with the outpatient consultation with independent
inﬂ uence of 11.8 %; whereas one subscale of the SF-36 (general health) was reversely 
associated with the inpatient consultation with independent inﬂ uence of 26.0%.
CONCLUSIONS: HRQoL was reversely associated with health services utilization 
and the independent inﬂ uence of HRQoL on health services utilization was smaller 
than that of socio-demographic and morbidity variables among primary care patients
in mainland China.
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OBJECTIVES: To investigate the preliminary impact of hospital global budgeting 
on the quality of care in Taiwan. METHODS: The logistic regression analysis was
employed to explore, after adjusting for case-mix using Charlson Comorbidity Index 
score, SARS effect and time trend, the impact of global budgeting on the mortality 30
days after admission, readmission 30 days after discharge and infection. Hospital 
inpatient claims of National Health Insurance from 2000 to 2004 were used. Global 
budgeting implemented on July 1, 2002 was represented by a dummy variable in the
model. RESULTS: The mortality rates 30 days after admission were 3.81, 3.87, 3.8, 
4.11 and 3.91 respectively; while the readmission rates 30 days after discharge were
17.3, 18.1, 18.5, 18.8 and 19.5. The corresponding infection rates were 0.76, 0.78,
0.75, 0.83 and 0.79. After the implementation of hospital global budgeting, patients
in district hospitals had lower readmission possibilities and insigniﬁ cant difference in 
infection. However, patients in medical centers and regional hospitals had higher 
readmission but lower infection probabilities. Patients in all hospitals had lower prob-
ability of death. CONCLUSIONS: Since the sector global budgeting in the ﬁ rst two 
years incurred stronger competition among hospitals, larger hospitals such as medical
centers and regional hospitals generated higher readmission rates, resulting in lower 
readmission rates for district hospitals. Nevertheless the mortality rates as well as the
